Short Interest in Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Expands By 1,602.8%

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totaling 75,842 shares, a growth of 1,602.8% from the December 31st total of 4,454 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 645,779 shares, the short-interest ratio is currently 0.1 days. Based on an average daily volume of 645,779 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, Zacks Research lowered Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

Daiichi Sankyo Price Performance

OTCMKTS DSNKY opened at $19.85 on Wednesday. The stock’s fifty day moving average price is $22.06 and its 200 day moving average price is $23.60. Daiichi Sankyo has a 1 year low of $19.71 and a 1 year high of $29.68. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.31 and a quick ratio of 1.60. The company has a market cap of $37.60 billion and a price-to-earnings ratio of 18.73.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody?drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.